SM04554

SM04554, also called dalosirvat, is an experimental scalp compound followed by hair-loss communities for possible regrowth. Discussion moved from hopes of lasting improvement to arguments about weak results and stalled development. The inspected participant post establishes no personal regrowth outcome, and the forum record does not establish efficacy, safety or current availability.

Why hair-loss communities discuss SM04554

• An experimental scalp compound called dalosirvat. SM04554 and SM-04554 are names for dalosirvat. It is a small molecule investigated for androgenetic alopecia, or pattern hair loss; the proposed approach involves Wnt, a signaling system involved in follicle growth. The sponsor describes its complete mechanism as unresolved. Official context Official context
• The appeal was growth through a different route. The 2017 HairLossTalk discussion hoped for finasteride-like benefit without its unwanted effects. Other posters questioned the dose response and the lack of updates. Those comparisons express what people wanted, not a head-to-head result or evidence of fewer side effects. HairLossTalk

Benefits people hoped for

• More coverage that might survive stopping. Reddit discussion imagined restarting dormant follicles and keeping gains after treatment ended. These are research-inspired expectations, not successful-use diaries. Reddit
• A participant post does not establish regrowth. On January 29, 2015, “SM04554 patient” said they were starting a US trial. They relayed an optimistic doctor and a nurse who had seen little growth in other participants. They did not report their own result. Personal report

Doses people discuss

• Topical 0.15% and 0.25% are trial-origin concentrations. Justinian repeated these two strengths in a January 2015 forum reply linking the trial registry. They are separate solution concentrations, not a demonstrated community dose range. The post does not establish an application volume, delivered milligrams or a consumer frequency. Bald Truth Talk

Half-life

• No usable human half-life in these discussions. No supported numerical estimate emerged. Hair growth after stopping does not measure drug clearance from blood or scalp. Bald Truth Talk Reddit

When change is reported

• No verified time to visible regrowth. The claimed participant’s post describes enrollment day and impressions of other patients, not their own before-and-after timeline. Replies differ over whether the early lack of visible growth was discouraging or simply too soon to judge. Personal report

How long effects might last

• Post-treatment growth remained a hope, not a permanent result. Reddit commenters used early follow-up findings to imagine lasting regrowth and stopping minoxidil. No inspected diary establishes lasting gains; the same author later acknowledged uncertainty about combinations. Reddit

Courses, breaks and repeat use

• Ninety days appears as a study course. A June 2015 forum reply described 90 days of treatment and roughly a month of follow-up. That is a retelling of a trial calendar, not an established on/off routine. No supported repeat-cycle schedule emerged. Bald Truth Talk

What needs caution

• Scalp irritation appears in formal testing. The Phase 2 presentation reports application-site redness, itching and burning/stinging or tingling, including events in the vehicle group. Its broad event definitions and limited follow-up do not establish long-term safety or prove every listed illness was drug-caused. Official context
• A pathway rumor can attach the wrong risk to a drug. In the Reddit discussion, a cancer-related animal story prompted another reader to distinguish a different developmental pathway and candidate. That exchange supplies neither a measured cancer risk for SM04554 nor reassurance that long-term Wnt modulation is harmless. Reddit
• A chemical name does not verify a consumer product. The FDA identity record expressly separates a substance identifier from approval. It does not show that a supplier’s bottle matches the clinical formulation, and this review did not verify a current approved SM04554 product or consumer availability. Official context

What the community record adds

• One participant’s post was repeated, not independently confirmed. Later Bald Truth Talk replies quote the January enrollment post. The nurse’s low-growth observation remains secondhand; repetition does not turn it into several nonresponder diaries. No same-author outcome update was established in the inspected material. Personal report Bald Truth Talk
• Blinding complicates even an honest trial account. A separate exchange notes that a person seeing no change might have received placebo. Posters also dispute whether encouragement from a clinic means anyone saw regrowth. Their argument explains why excitement, disappointment and an individual trial experience cannot identify a treatment effect alone. Bald Truth Talk
• Combination talk was speculative. Minoxidil, microneedling and tretinoin appear in proposals to obtain growth first and later hand maintenance over to SM04554. This is not an inspected successful stack, and it supplies no evidence that stopping another treatment would preserve its gains. Reddit
• Later disappointment needs attribution too. A later r/tressless reply says Phase 3 results ended development. That is a commenter’s pipeline claim, not a personal failure report or a verified sponsor announcement. Historical predictions of an imminent release should not be read as current availability. Reddit Bald Truth Talk

Separate research context

• Early follow-up explains the lasting-growth story. The sponsor’s Phase 2 presentation ends dosing at Day 90 and follows up at Day 135: 45 days, longer than the forum’s approximate month. It describes a signal for the 0.15% group versus vehicle over that interval, while warning that the analysis was not powered for efficacy comparison. This does not establish permanent growth. Official context
• Later results require more caution than the early headlines. The accessible registry-results copy for NCT03742518 lists two Week 48 primary hair-count comparisons with p-values of 0.540 and 0.745, which do not demonstrate superiority. Direct registry results were inaccessible here, and the copy has inconsistent enrollment metadata. These limitations prevent treating it as a definitive account of the program’s fate. Official context
• Trial schedules answer a different question from everyday use. The sponsor’s 2019 presentation describes once-daily topical 0.15% or 0.25% treatment for 48 weeks and follow-up to Week 54 in the later study. These are formal study arms, not a recommended regimen or a community-derived maintenance cycle. Official context